Three Cases of Lung Fibrosis in Patients With COVID-19

Click forward arrow on the bottom left of the video window to continue

Activity Title: Three Cases of Lung Fibrosis in Patients With COVID-19

Topic: COVID-19

Accreditation Type: AMA PRA Category 1 Credit(s)™

Release Date: July 31, 2020

Expiration Date: July 30, 2021

Estimated Time to Complete Activity: 30 minutes

Upon completion of the activity, participants should be able to:

  • Describe COVID-19 induced acute lung injury and ARDS
  • Discuss the potential progression of COVID-19 effects on the lungs
  • Discuss emerging clinical information regarding COVID-19 and chronic lung disease such as ILD
  • Review long-term management strategies for these patients

Amy L. Olson, MD, MSPH
Associate Professor
Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Hospital


  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ ANCC credit, or a certificate of participation—your CME/CE certificate will be available for download.



This activity is provided by The France Foundation.

This activity is intended for pulmonologists and other health care providers involved in the care of patients with and recovering from COVID-19.

Several reports of cases of pulmonary fibrosis resulting from COVID-19 disease have raised important questions in the pulmonary fibrosis community. Patients who are infected with COVID-19 may develop pneumonia and progress to severe respiratory failure, termed Acute Respiratory Distress Syndrome (ARDS), requiring mechanical ventilation. Post-ARDS fibrosis and pulmonary fibrosis that occurs in interstitial lung disease (ILD) have distinct differences. ILDs are chronic and progressive in nature. Post-ARDS fibrosis typically is not progressive, but nonetheless can be severe and limiting. Given the uncertainly of the novel coronavirus and the possibility of patients needing to manage complications for years to come, providing education and guidance to clinicians on how to best manage patients will be critical.

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.

Activity Staff Disclosures
Patrick Harty, PhD, has disclosed that his spouse is employed by Pfizer, Inc., and they hold stock in Pfizer, Inc. All other planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Content Creators:
The faculty listed below report that they have relevant financial relationships to disclose:

  • Dr. Olson does consulting for Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, and is the medical director for Medical Graphics. She is a speaker for Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech and does contract research for Boehringer Ingelheim Pharmaceuticals, Inc. through National Jewish Health.

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.


The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or